Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
about
Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascadeAdvantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patientsIn vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.Pericellular proteolysis in cancerJNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells.High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resectionDocosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKCδ- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions.Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma.Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray.Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.p38α MAPK mediates 17β-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells.
P2860
Q31087874-ABB74F42-D979-43C2-BE53-AC8B33709E4FQ33858614-1837327C-DDE8-4D35-93F7-9547C2274B6AQ34030193-C52A529A-FB2D-4037-A314-668CF456EBFDQ34430691-A7B8CDEF-F490-4E9D-AACC-B60BDA4740FFQ35232048-1D32A1D0-619B-47DD-AE24-4F54F7B1FB88Q36099278-C8180283-B546-4255-85F5-22EB7329F71CQ36139904-5807D00F-CCD9-4B11-9AFB-FFD67C698E3AQ36143607-7E06A0D0-9AC8-4B91-A6BA-BD87B97F905CQ36611325-833D68FE-6BCC-4FA0-96DA-ECABF4C26829Q37353423-68C56A54-79DF-404F-B366-CC076F8E289FQ37452215-D42DB303-3F16-4782-B802-94DA7691CC80Q38189275-B71F05FD-7646-4083-A75B-888C75D2F866Q38989294-D751147E-86AA-40ED-983C-6058CDCBEEF0Q40042049-554950A6-351A-44F3-8524-D769D7F209ACQ41460793-E99C56FE-34B7-4CEB-A6CA-726AC3F65CDBQ41875531-672CD7AB-62CC-4A8C-BB74-4B2D9A52E0EDQ41878292-D176FF85-E4D3-457C-B992-DEA8D7B47DCBQ42080528-1497E40B-BC44-456F-9FCE-DFA455F43C61Q53182315-A5C691A0-A8C5-4953-9A2D-A5F59767694F
P2860
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Plasminogen activator system, ...... colorectal cancer progression.
@en
Plasminogen activator system, ...... colorectal cancer progression.
@nl
type
label
Plasminogen activator system, ...... colorectal cancer progression.
@en
Plasminogen activator system, ...... colorectal cancer progression.
@nl
prefLabel
Plasminogen activator system, ...... colorectal cancer progression.
@en
Plasminogen activator system, ...... colorectal cancer progression.
@nl
P2093
P2860
P356
P1476
Plasminogen activator system, ...... colorectal cancer progression.
@en
P2093
P2860
P304
P356
10.1136/MP.53.6.307
P407
P577
2000-12-01T00:00:00Z